Skip Navigation

European Heart Journal 2003 24(6):504-514; doi:10.1016/S0195-668X(02)00797-2
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Staessen, J. A
Right arrow Articles by Birkenhäger, W. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Staessen, J. A
Right arrow Articles by Birkenhäger, W. H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Clinical perspective

Outcome beyond blood pressure control?

Jan A Staessena,*, Ji-Guang Wanga and Willem H Birkenhägerb

a Study Coordinating Centre, Laboratory of Hypertension, Department of Molecular and Cardiovascular Research, University of Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
b Erasmus University, Rotterdam, The Netherlands

* Corresponding author. Tel.: +32-16-34-7104; fax: +32-16-34-7106
E-mail address: jan.staessen@med.kuleuven.ac.be

Received 22 October 2002; accepted 23 October 2002

Key Words: Cardiovascular complications • Coronary heart disease • Hypertension • Stroke

The first 150 words of the full text of this article appear below.

1. Introduction

The last two decades witnessed the publication of a large number of clinical outcome trials of blood pressure lowering agents in hypertensive patients or normotensive subjects with a high cardiovascular risk profile. Placebo-controlled trials of antihypertensive drug treatment in middle-aged or older hypertensive patients predominantly with diastolic hypertension1 proved that a 5–6mmHg decline in diastolic pressure maintained over 5 years diminished the incidence of stroke by nearly 40% and that of coronary endpoints by 15%. Similarly, in older patients with isolated systolic hypertension, pharmacological intervention during 4 years reduced systolic pressure on average by 10mmHg and decreased cardiovascular mortality by 18%, all cardiovascular complications by 26%, stroke by 30%, and coronary events by 23%.2

Until recently, the consensual interpretation of the evidence produced by the outcome trials in hypertensive patients3–39 was that blood pressure is a risk factor amenable to intervention, lower levels leading to fewer complications. However, the HOPE . . . [Full Text of this Article]

2. Older vs newer antihypertensive drugs

3. Secondary prevention trials in high-risk patients

4. A meta-regression analysis

5. Benefit beyond blood pressure lowering?

6. Economic implications of trial results

7. Perspective on future trials in hypertension

8. Conclusions

Appendix A—Acronyms of trials


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
K. A. Griffin and A. K. Bidani
Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade
Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1054 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. F. O'Rourke and M. E. Safar
Relationship Between Aortic Stiffening and Microvascular Disease in Brain and Kidney: Cause and Logic of Therapy
Hypertension, July 1, 2005; 46(1): 200 - 204.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
S. G. Williams, D. T. Connelly, M. Jackson, A. Bennett, K. Albouaini, and D. M. Todd
Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?
Europace, January 1, 2005; 7(6): 554 - 559.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. K. Bidani and K. A. Griffin
Pathophysiology of Hypertensive Renal Damage: Implications for Therapy
Hypertension, November 1, 2004; 44(5): 595 - 601.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
I. Savelieva and A. John Camm
Atrial fibrillation and heart failure: natural history and pharmacological treatment
Europace, January 1, 2003; 5(s1): S5 - S19.
[Abstract] [Full Text] [PDF]